Details of the Drug

General Information of Drug (ID: DM09NZU)

Drug Name
RPh201
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 2 [1]
Cross-matching ID
TTD ID
D3YT8E

References

1 ClinicalTrials.gov (NCT03462121) A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease. U.S.National Institutes of Health.